Zhi Dong Pan
Direktor/Vorstandsmitglied bei MabPlex International Co., Ltd.
Profil
Zhi Dong Pan is currently a Director at MabPlex International Co., Ltd.
He previously served as a Member-Supervisory Board at Dalian Huarui Heavy Industry Group Co., Ltd.
He earned a doctorate degree from Dalian Maritime University in 2017.
Aktive Positionen von Zhi Dong Pan
Unternehmen | Position | Beginn |
---|---|---|
MabPlex International Co., Ltd.
MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Direktor/Vorstandsmitglied | 01.03.2020 |
Ehemalige bekannte Positionen von Zhi Dong Pan
Unternehmen | Position | Ende |
---|---|---|
DALIAN HUARUI HEAVY INDUSTRY GROUP CO., LTD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Zhi Dong Pan
Dalian Maritime University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
DALIAN HUARUI HEAVY INDUSTRY GROUP CO., LTD. | Non-Energy Minerals |
Private Unternehmen | 1 |
---|---|
MabPlex International Co., Ltd.
MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Health Technology |